Cardiff Oncology

Cardiff Oncology completed the sale of 8,571,429 shares of common stock and accompanying warrants at $1.05 each in a registered direct offering, yielding gross proceeds of approximately $10 million before fees. Officers and directors purchased 731,707 shares and warrants at $1.435 each; the warrants have an exercise price of $1.31, are exercisable no earlier than six months after issuance or after approval of the equity increase, and expire five and a half years after they first become exercisable. H.C. Wainwright & Co. acted as exclusive placement agent. Cardiff Oncology intends to use the net proceeds for working capital and general corporate purposes. » Plus sur de.investing.com

Cardiff Oncology will present preclinical data on its PLK1 inhibitor Onvansertib at the AACR 2026 annual meeting, which are intended to show that Onvansertib enhances the antitumor activity of trastuzumab‑deruxtecan (T‑DXd) and overcomes resistance in treatment‑refractory HER2‑low breast cancer models. Onvansertib is an orally administered PLK1 inhibitor currently being tested in a phase 2 trial in RAS‑mutant metastatic colorectal cancer and is being investigated in additional trials across various tumor types. The poster (abstract no. 329) will be made available on the company’s website after the presentation. » Plus sur de.investing.com

Onvansertib, combined with FOLFIRI and bevacizumab, showed an overall response rate of 72.2%, well above the 42% benchmark. Cardiff plans a global phase‑3 trial at 30 mg in the first half of 2026, subject to discussions with the FDA. The company has $58.3 million in cash, which is expected to fund operations until early 2027 but does not cover the anticipated costs of the phase‑3 trial. Pfizer invested $15 million and is serving as a CRO partner; Cardiff retains full rights to the program, is exploring additional indications, and anticipates regulatory and financial challenges. » Plus sur de.investing.com